Abstract
Background & Objective: Cannabis is the most widely used illicit drug. The two most important natural cannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). The THC content of cannabis has been increasing during the last years and recently appeared in the market as a series of synthetic cannabinoids with potent agonist activity. Recreational users frequently combine cannabis with other drugs of abuse as alcohol, amphetamines and derivatives, nicotine and cocaine. In addition, these subjects can be taking medicines for acute and chronic medical conditions. The increasing use of medicinal cannabis for chronic pain and neurological and psychiatric disorders can produce potential interactions with medications used for the symptomatic treatment of these or other diseases.
Conclusion: THC and CBD are metabolized mainly in the liver by cytochrome P-450 isoenzymes (mainly CYP2Cs and CYP3A4). In vitro studies indicate that THC and CBD both inhibit CYP1A1, 1A2 and 1B1 enzymes, and recent studies have indicated that CBD is also a potent inhibitor of CYP2C19 and CYP3A4. Both cannabinoids may interact with other medications metabolized by the same pathway or by inducers/inhibitors of the isoenzymes. Cannabis produces sedation, impairs psychomotor performance, and increases blood pressure and heart rate. Pharmacodynamic interactions with other sedatives can potentiate the central effects but can be decreased by psychostimulants. This review focuses on the interactions between cannabinoids and alcohol, other drugs of abuse, and prescription medicines.Keywords: Cannabis, cannabinoids, tetrahydrocannabinol, cannabidiol, interactions, alcohol, medicines.
CNS & Neurological Disorders - Drug Targets
Title:Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines
Volume: 16 Issue: 5
Author(s): Ana Lucia Arellano, Esther Papaseit*, Anna Romaguera, Marta Torrens and Magi Farré
Affiliation:
- Clinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol-IGTP. Carretera de Canyet s/n. 08916 Badalona,Spain
Keywords: Cannabis, cannabinoids, tetrahydrocannabinol, cannabidiol, interactions, alcohol, medicines.
Abstract: Background & Objective: Cannabis is the most widely used illicit drug. The two most important natural cannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). The THC content of cannabis has been increasing during the last years and recently appeared in the market as a series of synthetic cannabinoids with potent agonist activity. Recreational users frequently combine cannabis with other drugs of abuse as alcohol, amphetamines and derivatives, nicotine and cocaine. In addition, these subjects can be taking medicines for acute and chronic medical conditions. The increasing use of medicinal cannabis for chronic pain and neurological and psychiatric disorders can produce potential interactions with medications used for the symptomatic treatment of these or other diseases.
Conclusion: THC and CBD are metabolized mainly in the liver by cytochrome P-450 isoenzymes (mainly CYP2Cs and CYP3A4). In vitro studies indicate that THC and CBD both inhibit CYP1A1, 1A2 and 1B1 enzymes, and recent studies have indicated that CBD is also a potent inhibitor of CYP2C19 and CYP3A4. Both cannabinoids may interact with other medications metabolized by the same pathway or by inducers/inhibitors of the isoenzymes. Cannabis produces sedation, impairs psychomotor performance, and increases blood pressure and heart rate. Pharmacodynamic interactions with other sedatives can potentiate the central effects but can be decreased by psychostimulants. This review focuses on the interactions between cannabinoids and alcohol, other drugs of abuse, and prescription medicines.Export Options
About this article
Cite this article as:
Arellano Lucia Ana , Papaseit Esther *, Romaguera Anna , Torrens Marta and Farré Magi , Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines, CNS & Neurological Disorders - Drug Targets 2017; 16 (5) . https://dx.doi.org/10.2174/1871527316666170413104516
DOI https://dx.doi.org/10.2174/1871527316666170413104516 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Geriatric Psychopharmacology in Acute Settings
Current Psychopharmacology Fluid and Electrolyte Disorders in the Newborn: Sodium and Potassium
Current Pediatric Reviews Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews Vasodilator Effects of Bis-Dihydropyridines Structurally Related to Nifedipine
Medicinal Chemistry Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics
Current Topics in Medicinal Chemistry Nitric Oxide and Cardiovascular Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets From the Stretcher to the Pharmacys Shelf: Drug Leads from Medically Important Brazilian Venomous Arachnid Species
Inflammation & Allergy - Drug Targets (Discontinued) Disease Modification in Rheumatoid Arthritis and Osteoarthritis-Current and Emerging Targets and Therapeutics
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Postprandial Hypotension - Novel Insights into Pathophysiology and Therapeutic Implications
Current Vascular Pharmacology Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry An Unusual Case of Reversible Empty Sella
Endocrine, Metabolic & Immune Disorders - Drug Targets Design, Development and Optimization of Ramipril Solid Lipid Nanoparticles Using Solvent Emulsification and Evaporation Method
Nanoscience & Nanotechnology-Asia Utilizing Amines and Carbon Disulfide to Obtain Nitrogen- and Sulfur-containing Compounds under Green Conditions: A Review
Current Organic Chemistry Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Subject Index To Volume 6
Endocrine, Metabolic & Immune Disorders - Drug Targets Omega-3 Fatty Acids: from Biochemistry to their Clinical Use in the Prevention of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Descending Necrotizing Mediastinitis: Current Strategies for Diagnosis and Treatment
Current Respiratory Medicine Reviews Anti-Atherosclerotic Therapy Based on Botanicals
Recent Patents on Cardiovascular Drug Discovery Novel Strategies for the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Toll-Like Receptors and Inflammation in the CNS
Current Drug Targets - Inflammation & Allergy